Expansion of in vivo HDAd-transduced HSPCs by constitutive expression of tHMGA2 without additional treatment allows for therapeutically relevant transgene expression in HSPC progeny cells without clonal dominance.
Ontology highlight
ABSTRACT: We developed an in vivo hematopoietic stem and progenitor cell (HSPC) gene therapy approach that does not require HSC cell transplantation. To achieve therapeutically relevant numbers of corrected cells, we tested truncated HMGA2 instead of chemo-selection for enrichment of transduced HSPCs. We constructed HSC-tropic HDAd5/35++ vectors expressing a 3’UTR HMGA2 truncated gene and a GFP reporter gene. A SB100x transposase vector was used to mediate random integration of the tHMGA2/GFP transgene cassette. Mice were mobilized by subcutaneous injections of G-CSF and AMD3100/Plerixafor and intravenously injected with the integrating tHMGA2/GFP vector. This resulted in slow but progressive competitive expansion of GFP+ PBMCs, reaching about 50% by week 44 with further expansion in secondary recipients. Expansion occurred at the level of HSCs as well as at the level of myeloid, lymphoid, and erythroid progenitors within the bone marrow and spleen. Importantly, based on genome-wide integration site analyses, expansion was polyclonal, without any signs of clonal dominance. The results were validated in humanized mice. This is the first demonstration that simple subcutaneous and intravenous injections of mobilization drugs and HDAd vectors can trigger autocatalytic, self-limiting expansion of in vivo transduced HSPCs resulting in marking rates that, theoretically, are curative for hemoglobinopathies.
ORGANISM(S): Mus musculus
PROVIDER: GSE268678 | GEO | 2024/10/08
REPOSITORIES: GEO
ACCESS DATA